Keytruda may let some bladder cancer patients avoid bladder removal
NCT ID NCT05406713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether the immunotherapy drug Keytruda (pembrolizumab) can help people with muscle-invasive bladder cancer avoid having their bladder removed. About 46 participants will receive two cycles of Keytruda, then doctors will check if the cancer has completely responded. Those who respond well will continue Keytruda and be monitored closely, while others will proceed with standard treatments like surgery or radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab (Keytruda)
What this could lead to
If successful, this could offer a way for some patients with muscle-invasive bladder cancer to keep their bladder while still controlling the cancer.
What could go wrong
This is a small, early-phase trial with only 46 participants. The treatment may not work for everyone, and some patients may still need surgery or face side effects from immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87102, United States